Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for ...

New research suggests semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, could help people reduce their alcohol consumption.

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

"These results suggest that anti-obesity medication use, with relatively safe, effective, and sustainable weight loss, may be ...

The obesity market size is projected to witness growth from 2024 to 2034 due to the rising prevalence of obesity. This expansion is expected to be fu ...

Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s expected to curtail widespread access to cheaper copies of the popular ...

Desperation for ‘weight-loss’ drug that’s used to treat type-2 diabetes is real. Break-ins at pharmacies have also been ...